Pfizer Inc vs T Rowe Price Group Inc — how do they compare? Pfizer Inc trades at $24.91 (market cap $142.14B), while T Rowe Price Group Inc trades at $116 (market cap $25.20B). The key difference: Pfizer Inc is far larger — about 5.6× T Rowe Price Group Inc's market cap, and Pfizer Inc pays the higher dividend (6.9%). Which is the better fit depends on your goals.
| PFE | TROW | |
|---|---|---|
Market Cap | $142.14B | $25.20B |
Volume | 29,869,932 | — |
Sector | Health | Financials |
52-Week High | $28.56 | $120.16 |
52-Week Low | $23.29 | $86.19 |
Enterprise Value | $192.80B | $21.91B |
Dividend Yield | 6.9% | 4.42% |
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.83, up 0.32% today, with a neutral technical signal and bearish moving averages. The company reported revenue of $62.58B in 2025, with a net income margin of 11.83%, and has beaten EPS estimates for the last three quarters. Recent news highlights pipeline developments in oncology and obesity, with a consensus analyst price target of $28.25.
PFE offers a stable dividend and trades below analyst targets, but faces headwinds from patent expirations and volatile cash flows. The stock presents value with a P/E of 19.04, though growth depends on successful drug launches and navigating post-COVID revenue normalization.
T. Rowe Price (TROW) trades at $117.61, up 0.22% today, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $2.52, beating expectations, and maintains strong profitability with a 28.28% net margin. Recent news highlights the launch of an actively managed crypto ETF and AUM reaching $1.89 trillion in June 2026.
The stock presents a value opportunity with a P/E of 12.59, but faces mixed analyst sentiment with a consensus Hold rating. Upside potential exists if earnings momentum continues, while risks include market volatility impacting asset management fees and competitive pressures in the investment industry.
Trailing returns across standard periods
Latest headlines on both assets
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →